Designing a biosimilar blueprint for your practice

Dr. Robert Rifkin and a team of expert clinical specialists and business advisors help you understand biosimilars from the U.S. Food and Drug Administration (FDA) perspective. While similar to biologic reference products, biosimilars have unique operational, clinical, and financial decision points critical to successfully implementing these therapies in your practice.

 
 
 

Ask us how we can help.

We can help your practice navigate the biosimilar pipeline with confidence. If you have questions on adopting biosimilars at your practice, please submit your question here and someone from our team will contact you.

 

Foundation & Science Behind Biosimilars

In our first session, Dr. Robert Rifkin, McKesson’s Medical Director of Biosimilars, and Tim Ho, Clinical Specialist, provide a foundational understanding of biosimilars. Their conversation covers the differences between generics and biosimilars, the FDA’s position and guidelines, and the science behind developing biosimilar therapies.

Biosimilars Across Specialties

In our second session, Derek Burns, Clinical Specialist, discusses new biosimilar expansion across specialties and what your practice can do to begin preparing. He also covers clinical considerations of non-oncology practices and how to develop a biosimilar action plan specific to your practice.

Industry Outlook & Emerging Trends

In our final session, Jason Ballash, Director of Multisource Programs, and John Griffith, Director of Clinical Services, take a look at the path ahead for the biosimilars. They provide an insightful overview of the biosimilar pipeline, highlighting notable launches on the horizon with a clinical perspective on trends in the market.